8-K: NextCure Advances B7-H4 Antibody-Drug Conjugate Program Targeting Women's Cancers

NextCure is progressing its LNCB74 antibody-drug conjugate (ADC) program, targeting B7-H4 for breast, endometrial, and ovarian cancers, with an IND submission expected in Q4 2024 and proof-of-concept (POC) data anticipated in 2025.

Summary

• NextCure is developing LNCB74, an antibody-drug conjugate (ADC) targeting B7-H4, a protein overexpressed in several cancers.
• The company expects to submit an Investigational New Drug (IND) application in the fourth quarter of 2024.
• LNCB74 is designed with a differentiated glucuronidase cleavable linker for improved safety and efficacy.
• The company has completed a GLP toxicology study and GMP manufacturing for a Phase 1 trial.
• Proof-of-concept (POC) data is expected in 2025.
• NextCure has approximately $75 million in cash on hand as of the end of Q3, providing a cash runway into the second half of 2026.
• The initial focus is on breast, endometrial, and ovarian cancers, which have a high unmet need.
• The company is leveraging its deep expertise in B7-H4 and collaborating with LegoChem Biosciences (LCB) for ADC development.

Sentiment

Score: 7

Explanation: The document presents a positive outlook on the company's ADC program with clear milestones and a strong cash position. However, it also acknowledges the inherent risks in drug development and the company's history of losses, which tempers the overall sentiment.

Positives

• LNCB74 utilizes a differentiated glucuronidase cleavable linker, which may lead to improved safety and efficacy.
• The company has completed key preclinical steps, including GLP tox studies and GMP manufacturing.
• NextCure has a strong cash position of approximately $75 million, providing a runway into the second half of 2026.
• Preclinical data shows potent anti-tumor activity in various models.
• The company has a co-development partnership with LCB, leveraging their ADC expertise.
• The company has received favorable pre-IND feedback from the FDA.
• The company has a validated patient selection assay.

Negatives

• The company has a limited operating history and no products approved for commercial sale.
• The company has a history of significant losses.
• The company needs to obtain additional financing in the future.
• The approach to drug discovery is unproven.
• The company is dependent on key personnel.

Risks

• The impacts of the COVID-19 pandemic could affect the company's business, including clinical trials and operations.
• Positive results in preclinical studies may not predict the results of clinical trials.
• There are risks related to clinical development, marketing approval, and commercialization.
• The company's approach to drug discovery is unproven.
• The company is dependent on key personnel.
• The company needs to obtain additional financing.

Future Outlook

The company anticipates submitting an IND application for LNCB74 in Q4 2024 and expects proof-of-concept data in 2025. The company plans to initiate a Phase 1 monotherapy study with dose escalation and expansion cohorts.

Management Comments

• The company will be hosting calls with members of the investment community, which may reference presentation materials.

Industry Context

The development of antibody-drug conjugates (ADCs) is a growing area in oncology, with several companies pursuing this approach. NextCure's LNCB74 is targeting B7-H4, which is also being explored by other companies, including GSK, highlighting the potential of this target in women's cancers. The company is positioning itself as a competitor in the ADC space.

Comparison to Industry Standards

• Several companies are developing B7-H4 targeted ADCs, including SGN-B7H4V, XMT-1660, HS-20089, AZD8205, and DB-1312/BG-C9074.
• NextCure's LNCB74 differentiates itself with a glucuronidase cleavable linker, while others use val-cit, protease, or other cleavable linkers.
• LNCB74 uses a site-specific conjugation method, while some competitors use stochastic conjugation.
• LNCB74 uses a hG1-LALA Fc modification to limit immune cell engagement, while some competitors use a WT hG1 Fc which can engage immune cells.
• The company is using a MMAE payload, which is common in ADCs, but is using a DAR of 4.
• Some competitors have reported clinical responses, such as partial responses (PR) and complete responses (CR) in various cancers, which NextCure will be aiming to match or exceed.

Stakeholder Impact

• Shareholders may see potential value creation from the advancement of the LNCB74 program.
• Employees are involved in the development and execution of the clinical program.
• Patients with breast, endometrial, and ovarian cancers may benefit from the development of a new treatment option.
• The company's collaboration with LCB impacts both companies' stakeholders.

Next Steps

• Submit an IND application for LNCB74 in Q4 2024.
• Initiate a Phase 1 monotherapy study for LNCB74.
• Obtain proof-of-concept (POC) data for LNCB74 in 2025.

Key Dates

Keywords

Antibody-drug conjugate, ADC, B7-H4, LNCB74, Cancer, Oncology, Breast cancer, Ovarian cancer, Endometrial cancer, Glucuronidase linker, Clinical trial, IND, MMAE, LegoChem Biosciences, Drug development